Project Grant R21CA313364
Award Date 5/14/26
Completion Date 4/30/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research into novel dendritic cell-based immunotherapy for solid tumors. The project will deliver mechanistic characterization and preclinical development of AB7H3-TLR4 chimeric antigen receptor (CAR) dendritic cells (DCs)—engineered immune cells designed to overcome tumor immune...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) effective April 1, 2026, through March 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The project, titled "Rational Design of Next-Generation Engineered T Cells for Enhanced Cancer Immunotherapy," focuses on developing improved chimeric antigen receptor (CAR) T cell therapies by enhancing T cell persistence...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $3.18 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. Awarded on September 24, 2025, with a completion date of August 31, 2029, this research project will generate fundamental knowledge about how NK cells may suppress the efficacy of ICT in tumor treatment. The study will...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $645,185 Project Grant on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate an innovative immunotherapy combination approach for glioblastoma treatment. The research will deliver two primary products: (1) mechanistic studies establishing how long-acting Interleukin-7 (IL-7) combined with oncolytic virus therapy improves CD8+ T cell...
- Federal Grant Award Summary The National Cancer Institute awarded a $542,644 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on developing radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The research leverages a breakthrough discovery identifying...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $1,276,947 under the Cancer Treatment Research program (CFDA 93.395) for research on microbial neoantigen cancer vaccines. The award, initiated August 1, 2025, with completion targeted for May 31, 2030, supports fundamental and applied research to improve the therapeutic efficacy and safety of microbial vector-based neoantigen...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), through its Cancer Research Manpower program (CFDA 93.398), awarded The Washington University a Project Grant of $333,504 effective July 1, 2025, through July 31, 2027. This award funds research investigating the dynamics and function of peritoneal myeloid cells during colorectal cancer (CRC) peritoneal dissemination and the implications for immunotherapy. The research aims to elucidate the unique roles of myeloid...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $2.47 million under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, with completion targeted for July 31, 2029. This grant supports fundamental research investigating the role of wild-type isocitrate dehydrogenase 1 (WT-IDH1) metabolism in reprogramming the tumor microenvironment of glioblastoma. The research encompasses both in vitro and in...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The primary deliverable is the first-in-man clinical imaging study of [77Br]Br-WC-DZ, a bromine-77 ligand targeting...